Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo topical suspension Clear all
Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.

NCT03509675
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction
Interventions
Ibuprofen suspension 5mg/100ml, Placebos
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of PG101 for Dry Eye Syndrome

NCT02078661
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
PG101
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene and betamethasone suspension, Taclonex, Placebo
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PRN473 (SAR444727), Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

NCT02723539
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
MBN-101, Placebo
Drug
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Fresno, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 23, 2026, 6:55 PM EDT
Not listed Phase 4 Interventional

Post Intravitreal Injection Topical NSAID vs. Patching

NCT03918590
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching
Drug · Other
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

NCT02485717
View directory record Official record
Conditions
Scabies
Interventions
spinosad topical suspension, 0.9%, Placebo
Drug · Other
Lead sponsor
ParaPRO LLC
Industry
Eligibility
4 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Elk Grove, California • Kissimmee, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

NCT02485704
View directory record Official record
Conditions
Scabies
Interventions
spinosad topical suspension, 0.9%, Placebo
Drug · Other
Lead sponsor
ParaPRO LLC
Industry
Eligibility
4 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Long Beach, California • Kissimmee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%, Placebo
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

NCT01312402
View directory record Official record
Conditions
Infantile Nystagmus Syndrome
Interventions
topical brinzolamide 1% in 5mL ophthalmic medication, Placebo in 5 mL dispenser
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 23, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional Results available

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

NCT02222207
View directory record Official record
Conditions
Macular Degeneration
Interventions
Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
Drug · Procedure
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Sep 23, 2026, 6:55 PM EDT
Recruiting Phase 3 Interventional

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression

NCT05058287
View directory record Official record
Conditions
Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
Interventions
Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

NCT06172257
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01), Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 85 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
42
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 23, 2026, 6:55 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

NCT05066997
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01), Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 85 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 23, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

NCT04630158
View directory record Official record
Conditions
Chronic Ocular Pain
Interventions
SAF312 Placebo, SAF312
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Mission Hills, California • Newport Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 23, 2026, 6:55 PM EDT